Nephros is a medical instruments & supplies business based in the US. Nephros shares (NEPH) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was $1.50 – a decrease of 7.97% over the previous week.
Offer ends 4/1/25. Customer must fund their Active invest account with at least $50 within 30 days of opening the account. Probability of customer receiving $2,000 is 0.028%. See full terms and conditions at https://www.sofi.com/greenintwoterms/.
Open an account.Provide your personal information and sign up.
Fund your account.Deposit funds into your account by linking your banking information or transfer funds from another trading account.
Search for the stock name – NEPH.Search for the stock by name or ticker symbol.
Buy the stock. Place your order. It's that simple.
Buy Nephros stock from these online trading platforms
Compare special offers, low fees and a wide range of investment options among top trading platforms.
1 - 4 of 4
What is the Finder Score?
The Finder Score crunches 147 key metrics we collected directly from 18+ brokers and assessed each provider’s performance based on nine different categories, weighing each metric based on the expertise and insights of Finder’s investment experts. We then scored and ranked each provider to determine the best brokerage accounts.
We update our best picks as products change, disappear or emerge in the market. We also regularly review and revise our selections to ensure our best provider lists reflect the most competitive available.
Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.
Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.
Nephros stock price (NASDAQ: NEPH)
Use our graph to track the performance of NEPH stocks over time.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Nephros price performance over time
Historical closes compared with the close of $1.5 from 2025-03-20
1 week (2025-03-14)
-7.97%
1 month (2025-02-21)
-1.75%
3 months (2024-12-20)
-2.60%
6 months (2024-09-20)
-18.48%
1 year (2024-03-21)
-32.13%
2 years (2023-03-21)
31.58%
3 years (2022-03-21)
4.12
5 years (2020-03-20)
6.7
Is Nephros stock undervalued or overvalued?
Valuing Nephros stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Nephros's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Nephros's P/E ratio
Nephros's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 163x. In other words, Nephros shares trade at around 163x recent earnings.
That's relatively high compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The high P/E ratio could mean that investors are optimistic about the outlook for the shares or simply that they're over-valued.
Nephros's EBITDA
Nephros's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $142,000.
The EBITDA is a measure of a Nephros's overall financial performance and is widely used to measure a its profitability.
Nephros financials
Revenue TTM
$14.2 million
Operating margin TTM
8.19%
Gross profit TTM
$8.7 million
Return on assets TTM
0.03%
Return on equity TTM
0.87%
Profit margin
0.52%
Book value
$0.81
Market Capitalization
$17.2 million
TTM: trailing 12 months
Nephros share dividends
We're not expecting Nephros to pay a dividend over the next 12 months.
Have Nephros's shares ever split?
Nephros's shares were
split on a 1:9 basis on 9 July 2019
. So if you had owned 9 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Nephros shares – just the quantity. However, indirectly, the new 800% higher share price could have impacted the market appetite for Nephros shares which in turn could have impacted Nephros's share price.
Nephros share price volatility
Over the last 12 months, Nephros's shares have ranged in value from as little as $1.3643 up to $2.55. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Nephros's is 1.199. This would suggest that Nephros's shares are a little bit more volatile than the average for this exchange and represent, relatively-speaking, a slightly higher risk (but potentially also market-beating returns).
Nephros overview
Nephros, Inc. , a commercial-stage company, develops and sells water solutions to the medical and commercial markets in the United States. It offers ultrafiltration products that are used in dialysis centers for the removal of biological contaminants from water and bicarbonate concentrate; and in hospitals for the prevention of infection from waterborne pathogens, such as legionella and pseudomonas, as well as in military and outdoor recreation, commercial, and other healthcare facilities. The company also manufactures and sells water filters that enhance the taste and odor of water, as well as reduce biofilm, cysts, particulates, and scale build-up in downstream equipment. It markets its products to food service, hospitality, convenience store, and health care markets, as well as medical institutions. The company was incorporated in 1997 and is headquartered in South Orange, New Jersey. .
Frequently asked questions
What percentage of Nephros is owned by insiders or institutions? Currently 12.867% of Nephros shares are held by insiders and 44.695% by institutions.When does the fiscal year end for Nephros? Nephros's fiscal year ends in December.Where is Nephros based? Nephros's address is: 380 Lackawanna Place, South Orange, NJ, United States, 07079What is Nephros's ISIN number? Nephros's international securities identification number is: US6406714005What is Nephros's CUSIP number? Nephros's Committee on Uniform Securities Identification Procedures number is: 640671301
A deep dive into the highlights and limitations of Robinhood.
Advertiser disclosure
Finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which Finder receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. Finder compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.
We update our data regularly, but information can change between updates. Confirm details with the provider you're interested in before making a decision.
How likely would you be to recommend Finder to a friend or colleague?
0
1
2
3
4
5
6
7
8
9
10
Very UnlikelyExtremely Likely
Required
Thank you for your feedback.
Our goal is to create the best possible product, and your thoughts, ideas and suggestions play a major role in helping us identify opportunities to improve.
